LifeMD’s (LFMD) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of LifeMD (NASDAQ:LFMD) in a research note released on Friday morning, Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Several other brokerages have also recently weighed in on LFMD. BTIG Research increased their price target on shares of LifeMD from $13.00 to $14.00 and gave the company a buy rating in a research report on Tuesday, April 23rd. HC Wainwright reiterated a buy rating and set a $12.00 target price on shares of LifeMD in a report on Friday, May 10th. B. Riley restated a buy rating and set a $12.00 price target on shares of LifeMD in a report on Tuesday, May 21st. Finally, KeyCorp dropped their price objective on LifeMD from $12.00 to $10.00 and set an overweight rating for the company in a report on Thursday, July 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $12.17.

LifeMD Trading Up 4.0 %

LFMD stock traded up $0.21 during trading on Friday, hitting $5.43. 536,669 shares of the company traded hands, compared to its average volume of 843,066. The company has a 50-day moving average of $6.90 and a 200-day moving average of $8.13. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.94 and a current ratio of 0.99. LifeMD has a 1 year low of $3.46 and a 1 year high of $12.88. The firm has a market capitalization of $226.74 million, a PE ratio of -7.34 and a beta of 1.24.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to analysts’ expectations of $48.47 million. During the same period in the prior year, the firm earned ($0.23) EPS. Analysts predict that LifeMD will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of LifeMD

Large investors have recently bought and sold shares of the company. ClariVest Asset Management LLC raised its position in shares of LifeMD by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock worth $631,000 after acquiring an additional 2,600 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in LifeMD by 266.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after purchasing an additional 3,348 shares during the period. Quest Partners LLC bought a new position in LifeMD in the second quarter worth $31,000. EntryPoint Capital LLC purchased a new position in LifeMD during the first quarter valued at $89,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of LifeMD during the 2nd quarter valued at $88,000. 35.52% of the stock is owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.